In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
#psychedelics – ““A rather large dose of LSD might be 300 micrograms, and a rather large dose of psilocybin might be 30 milligrams. A rather large dose of mescaline would be 300 milligrams,” he says. That means you need much more mescaline to achieve an experience comparable to the intensity of LSD or psilocybin, which can make it less appealing as a research subject. Further, Hendricks says, “Mescaline may also be more associated with nausea. If you have a choice between one compound that causes nausea and another that doesn’t, which one do you choose?””
#psychedelics – “It looks like a pill, and it tastes just like one…but this isn’t your typical over-the-counter medication. Leading the charge in natural drug development, Vancouver-based Filament Health is pioneering a breakthrough medical-grade ayahuasca pill.
This novel concept could potentially help individuals access an authentic ayahuasca experience without requiring a trip to South America.
The Company is on the brink of obtaining FDA authorization to initiate its pioneering Phase 1 clinical trial for its ayahuasca pill, with expectations that it will take place during the first six months of 2023.”
#cbdproducts – “Stakeholders should keep a close eye on the legislative process and consider lobbying efforts where appropriate. Manufacturers and retailers of CBD products must remain steadfast in their compliance efforts in spite of ongoing uncertainty. Even though the FDA has punted on its rulemaking, we expect to continue to see enforcement actions against those with products that arguably violate the FD&C Act. Companies marketing CBD products should ensure that they do not make any unsubstantiated health claims on packaging, websites, or other marketing materials, which have been a focus of the FDA’s enforcement efforts. CBD should not be marketed as a dietary supplement. Packaging of CBD products should clearly identify CBD as an ingredient and the source of the CBD. Manufacturers and marketers should also take steps to ensure that the packaging and products do not appeal to children. Those producing CBD infused beverages and foods might even reconsider their product lines in light of the risks associated with such CBD infused foods and beverages.”
#cannabisindustry – “In a major policy shift, Twitter is allowing “approved” and state-legal cannabis companies and other advertisers to post ads in the U.S. for regulated THC and CBD products, accessories and services, the social media platform has disclosed.
“We permit approved Cannabis (including CBD– cannabinoids) advertisers to target the United States” provided a slew of conditions are met, Twitter said on its website under the heading, “Drugs and drug paraphernalia.”….
“American cannabis companies, brands and purveyors will need to pass through a Twitter advertiser approval process to ensure they are legitimate and educated on the platform,” AdCann reported.
“Once approved, industry marketers will have access to Twitter’s entire suite of advertising products including promoted tweets, promoted product opportunities, location-specific takeovers, in-stream video sponsorships and partner publication features.””
#cannabisindustry – “But with the Occupational Safety and Health Administration’s investigation of Trulieve, one of the largest multistate cannabis companies, the spotlight now shines on the safety of the licensed cannabis workplace itself and whether on-duty contact with cannabis may pose health hazards.
The Trulieve investigation signals that OSHA will regulate the workplace like any other, notwithstanding the federal illegality of cannabis, and may soon classify ground cannabis dust as a “hazardous chemical.”
Cannabis companies should consider OSHA’s investigation a harbinger of major compliance issues to come, as well as a call to recognize and respond to the hazards that their employees may be exposed to at work.”
#californiacannabis – “Two appeals of cannabis projects in Santa Barbara County fell through at last week’s meeting of the California Coastal Commission, with the commission agreeing to the staff’s assertion that there was nothing wrong with either project — technically — according to how the county’s cannabis ordinance is written and executed.
Instead, this latest batch of cannabis-related appeals out of Santa Barbara — against a four-acre grow outside Carpinteria and a cannabis retail dispensary on the small beach town’s Santa Claus Lane — raised questions among several commissioners over whether the county may need to go back to the drawing board and revisit an ordinance that has caused countless conflicts between county officials, cannabis companies, and concerned citizens in the years since being implemented.”
#cannabisindustry – “Former Virginia Gov. Ralph Northam signed an adult-use cannabis legalization bill into law nearly two years ago—in April 2021—but commercial adult-use sales won’t be launching any time soon after lawmakers rejected legislation this week to create a regulated market.
The Republican-controlled House of Delegates voted Feb. 14 to kill a bill, sponsored by Sen. Adam Ebbin, D-Alexandria, that would have allowed an adult-use market to launch in 2024, according to a local WRIC report.
Under the law signed by Northam in 2021, adults 21 and older can legally possess up to an ounce of cannabis and grow up to four plants at home, but there is no way to purchase cannabis for recreational use in the state.
The 2021 legislation set a 2024 target date to launch adult-use sales, but also included a reenactment clause that requires the Virginia Legislature to reauthorize certain provisions and establish a regulatory framework for a commercial market.”